Last
Update:
December 05, 2008
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
Ninth International Congress on Drug Therapy in HIV Infection
|
-
POSTER
Virological response with fully active etravirine after 48 weeks of treatment:
pooled results from the DUET-1
and DUET-2 trials
N Clumeck, B Clotet, M Johnson, et al
PDF Poster
-
POSTER
Reduction in AIDS-defining events/deaths with etravirine compared to
placebo: pooled DUET 48-week results
R Haubrich, J Eron, M Thompson, et al
PDF Poster
-
POSTER
Pharmacokinetics of Once-Daily Etravirine (ETR) Without and With Once-Daily
Darunavir/
Ritonavir (DRV/r) in Antiretroviral-Naïve HIV-1 Infected Adults
J Lalezari, E DeJesus, O Osiyemi, et al
PDF Poster
-
POSTER
Cost-minimisation analysis of the use of etravirine or raltegravir in
treatment-experienced HIV-1-infected patients
E Smets, S Martin
PDF Poster
-
POSTER
Safety and tolerability of etravirine in hepatitis B and/or C
co-infected patients in DUET-1 and DUET-2:
pooled 48-week results
B Clotet, C Katlama, A Lazzarin, et al
PDF Poster
-
POSTER
Switching from enfuvirtide to etravirine – efficacy results from the etravirine
early access programme
E Ribera, M Loutfy, E Florence, et al
PDF Poster
-
POSTER
Etravirine protects the activity of darunavir in the DUET trials
M Peeters, J Vingerhoets, L Tambuyzer, et al
PDF Poster
-
POSTER
Activity of etravirine on different HIV-1 subtypes: Week 48 data of the pooled
DUET trials and in-vitro
susceptibility in treatment-naïve patients
J Vingerhoets, H Azijn, L Tambuyzer, et al
PDF Poster
-
POSTER
Antiretroviral treatment use and HIV RNA suppression rates for 941 European
patients in the etravirine
early access programme
E Florence, S De Wit, A Castagna, et al
PDF Poster
-
POSTER
Durability of virologic response to etravirine is not affected by time to
reach
virologic response
A Mills, La Cotte, S Smith, et al
PDF Poster
-
POSTER
Effect of etravirine on cytochrome P450 isozymes assessed by the
Cooperstown
5+1 cocktail
M Schöller-Gyüre, TN Kakuda, T Stevens,et al
PDF Poster
-
POSTER
Reduction in AIDS-defining events/death with etravirine compared to
placebo:
pooled DUET 48-week results
R Haubrich, J Eron, M Thompson, et al
PDF Poster
-
POSTER
Pharmacokinetics and pharmacodynamics of etravirine in
treatment-experienced
HIV-1-infected patients: pooled 48-week results of DUET-1 and DUET-2
TN Kakuda, M Peeters, C Corbett, et al
PDF Poster
-
POSTER
Treatment Response among HIV Patients Co-enrolled in the Etravirine (ETR)
and Raltegravir (RAL) Expanded Access Programs (EAPs) at Kaiser Permanente
Kerrigan H, Towner W, Klein D, Follansbee S
PDF Poster
XVII International AIDS
Conference
|
-
A WEEK IN REVIEW FEATURED
REPORT
POSTER
Efficacy, Safety and Tolerability of Etravirine With and Without Darunavir
and/or Raltegravir in
Treatment-Experienced
Patients: Preliminary Analysis of TMC125-C214 Early Access Program
(EAP)
in the US
W Towner, Z Haigney, MG Sension, et al
PDF Poster
-
A WEEK IN REVIEW FEATURED
REPORT
POSTER
48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline
characteristics on virologic
response to etravirine
P Cahn, J-M Molina, W Towner, et al
PDF Poster
-
A WEEK IN REVIEW FEATURED
REPORT
POSTER
The impact of background regimen on virologic response to etravirine:
pooled 48-week analysis of
DUET-1 and DUET-2
G Di Perri, J Valdez Madruga, K Sathasivam et al
PDF Poster
-
POSTER
Impact of etravirine on hospitalizations and hospital-related
costs:48-week findings from pooled DUET trials
K Gebo, S Martin, C Corbett, G De Smedt
PDF Poster
 -
A WEEK IN REVIEW FEATURED
REPORT
POSTER
Analysis of US costs of full virologic suppression for treatment
experienced, HIV-infected patients in the DUET trials
S Martin, AM Hill
PDF Poster
-
POSTER
Bioavailability of the 100mg etravirine tablet dispersed in water and of
the 25mg pediatric tablet formulation
M Schöller-Gyüre, TN Kakuda, RM Van Solingen-Ristea, et al
PDF Poster
-
POSTER
Incidence and severity of nervous system and psychiatric events are
similar with etravirine versus placebo:
pooled 48-week
data from the Phase III DUET studies
C Katlama, T Campbell, M Schechter, et al
PDF Poster
-
A WEEK IN REVIEW FEATURED
REPORT
POSTER
The incidence of rash observed with the NNRTI etravirine in the Phase III
DUET trials using pooled 48-week data
A Mills, B Grinsztejn, C Katlama, et al
PDF Poster
-
A WEEK IN REVIEW FEATURED
REPORT
POSTER
Combined darunavir and
etravirine resistance analysis of the pooled DUET trials: when can we
spare the other
new classes?
R Haubrich, JM Schapiro, J Vingerhoets,et al
PDF Poster
-
POSTER
Pharmacokinetics of etravirine are not affected by sex, age, race,
treatment duration or use of enfuvirtide in
HIV-1-infected subjects
TN Kakuda, M Schöller-Gyüre, M Peeters, et al
PDF Poster
-
POSTER
Etravirine has no effect on fetal development in rats and rabbits
A Raoof, S Lachau-Durand, J Verbeeck ,et al
PDF Poster
-
Bioavailability of the 100mg etravirine tablet dispersed in water and of the
25mg pediatric tablet formulation
M.
Schöller-Gyüre, T.N. Kakuda, R.M. Van Solingen-Ristea, et al
Abstract
-
Etravirine associated mutations and NNRTI hypersensitizing mutations among
HIV-1 subtype-C
.infected
etravirine-
naïve South Indian patients failing therapy.
S. Saravanan, M. Vidya, P. Balakrishnan , et al
Abstract
-
Treatment experience with etravirine and optimised background regimen: 24 week
data from a single centre cohort
C.
Scott, R. Jogiya, A. Teague, et al
Abstract
-
Impact of TMC125 on hospitalizations and hospital related costs: 24-week
findings from pooled DUET trials
K.
Gebo, S. Martin, C. Corbett, G. De Smedt
Abstract
2008 International
HIV Drug Resistance Workshop
|
POSTER
Determination of phenotypic clinical cut-offs for etravirine (ETR): pooled Week
24
results of the DUET-1 and DUET-2 trials
M Peeters, S Nijs, J Vingerhoets, et al
PDF Poster
POSTER
Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR)
G Picchio, J Vingerhoets, N Parkin,
et al
PDF Poster
POSTER
An update of the list of NNRTI mutations associated with decreased virologic
response to
etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical
trial data
J Vingerhoets, M Peeters, H Azijn, et al
PDF Poster
17th Canadian Conference
on HIV/AIDS Research
|
9th International
Workshop on Clinical Pharmacology of HIV
|
A WEEK IN REVIEW FEATURED REPORT
POWERPOINT PRESENTATION
Emerging mutations in patients with virological failure on etravirine (ETR;
TMC125) in the
DUET-1 and DUET-2 clinical trials
L. Tambuyzer, J. Vingerhoets, H. Azijn, et al
Slide
Presentation
POWERPOINT PRESENTATION
Combined PI and NNRTI Resistance Analysis of the Pooled DUET Trial:
Towards a Regimen-Based
Resistance Interpretation
JM Schapiro, J Vingerhoets, S Nijs, et al
Slide Presentation
15th Conference on Retroviruses and
Opportunistic
Infections |
-
POSTER
Development of vircoTYPE HIV-1 Resistance Analysis, Including Clinical
Cutoffs for TMC125,
a New NNRTI
B Winters, J
Vingerhoets, M Peeters, et al
PDF Poster
Abstract-
POSTER
DUET-2: Week-48 Results of a Phase III Randomized Double-blind Trial to
Evaluate the Efficacy and
Safety of TMC125 vs Placebo in 591 Treatment-experienced HIV-1-infected
Patients
M Johnson, T
Campbell, B Clote, et al
PDF
Poster
Abstract -
POSTER
Pharmacokinetics and Pharmacodynamics of the NNRTI TMC125 in
Treatment-experienced HIV-1-infected
Patients: Pooled 24-week Results of DUET-1 and DUET-2
T Kakuda, J Wade E
Snoeck, et al
PDF
Poster
Abstract -
POSTER
Pharmacokinetics of the
Next-generation NNRTI TMC125 in HIV-infected Children between 6 and
17 Years of Age
T Kakuda, C Konigs, C
Feiterna-Sperling, et al
PDF Poster
Abstract-
POSTER
Prevalence of Mutations with Effect on Virological Response to
Etravirine in Routine Clinical Samples
J Llibre, J Santos,
T Puig,, et al
PDF Poster
Abstract -
Etravirine-resistance Mutations in Patients with Virologic Failure on
Nevirapine or
Efavirenz-based HAART
B
Taiwo, B Chaplin, J Stanton, et al
Abstract-
POSTER
Evaluating the Role of Etravirine in the Second-line ART after Failing
an Initial NNRTI-based
Regimens in a Resource-limited Setting
S Sungkanuparph, W
Manosuthi, S Kiertiburanakul, et al
PDF Poster
Abstract
-
POSTER
Pooled 24-week results of DUET-1 and DUET-2: efficacy of TMC125 (etravirine;
ETR) in treatment-experienced HIV-1-infected patients
C Katlama, JM Gatell, JM Molina, et al
PDF Poster
-
POSTER
Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) safety
and tolerability in treatment-experienced, HIV-1-infected patients
G Di Perri, PM Girard, N Clumeck, et al
PDF Poster
-
POSTER
Impact of baseline NNRTI mutations on the virological response to TMC125
(etravirine; ETR) in the DUET-1 and DUET-2 Phase III clinical trials
J Vingerhoets, B Clotet, M Peeters , et al
PDF Poster
-
POSTER
Impact of TMC125, a next-generation NNRTI, on clinical outcomes (AIDS-defining
illnesses
and deaths): 24-week findings from a planned pooled analysis of the DUET studies
J Gatell, G Beatty, M Johnson, et al
PDF Poster
-
POSTER
No pharmacokinetic interaction between TMC125(etravirine; ETR) and paroxetine
in HIV-negative volunteers
M Schöller-Gyüre, TN Kakuda, S Bollen, et al
PDF Poster
-
POSTER
Thorough QT trial with TMC125 (etravirine; ETR) dosed at200mg bid and 400mg qd
in HIV-negative
volunteers
M Peeters, K Janssen, G De Smedt, et al
PDF Poster
The American
Conference for the Treatment of HIV- 2007
|
TMC125 in Combination With Medications Commonly Used in HIV
Infection:
Summary of Drug-Drug Interactions
T Surles, M Schöller-Gyüre, RM
Hoetelmans, et al
PDF Poster
POSTER
Development of a list of mutations associated with NNRTI resistance for use in
clinical research
L Tambuyzer, J Vingerhoets, H Azijn, et al
PDF Poster
|
Etravirine Conference Citations |
|
Conference
Archives 